NCT03874052 - Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 16, 2019

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRecurrent Secondary Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaRefractory Secondary Acute Myeloid Leukemia

Interventions

DRUG

Azacitidine

Given IV or SC

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration and biopsy

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow aspiration and biopsy

PROCEDURE

Echocardiography Test

Undergo ECHO

PROCEDURE

Punch Biopsy

Undergo skin punch biopsy

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Ruxolitinib

Given PO

DRUG

Venetoclax

Given PO

Trial Locations (3)

43210

SUSPENDED

Ohio State University Comprehensive Cancer Center, Columbus

75390

SUSPENDED

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

97239

RECRUITING

OHSU Knight Cancer Institute, Portland